OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
David M. Williams, Marc Evans
Diabetes Therapy (2020) Vol. 11, Iss. 10, pp. 2221-2235
Open Access | Times Cited: 17
David M. Williams, Marc Evans
Diabetes Therapy (2020) Vol. 11, Iss. 10, pp. 2221-2235
Open Access | Times Cited: 17
Showing 17 citing articles:
Therapeutic Advances in Diabetic Nephropathy
Hanny Sawaf, George Thomas, Jonathan J. Taliercio, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 2, pp. 378-378
Open Access | Times Cited: 88
Hanny Sawaf, George Thomas, Jonathan J. Taliercio, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 2, pp. 378-378
Open Access | Times Cited: 88
Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease
Javier Morales, Yehuda Handelsman
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 2, pp. 161-170
Open Access | Times Cited: 35
Javier Morales, Yehuda Handelsman
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 2, pp. 161-170
Open Access | Times Cited: 35
Proglucagon-Derived Peptides as Therapeutics
Ryan A. Lafferty, Finbarr O’Harte, Nigel Irwin, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 50
Ryan A. Lafferty, Finbarr O’Harte, Nigel Irwin, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 50
Alessandra Kobayati, Ahmad Haidar, Michael A. Tsoukas
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 5, pp. 769-787
Closed Access | Times Cited: 26
Efficacy of the Glucagon-Like Peptide-1 Agonist Exenatide in Patients Undergoing CABG or Aortic Valve Replacement: A Randomized Double-Blind Clinical Trial
Jesper Kjærgaard, Christian H. Møller, Sebastian Wiberg, et al.
Circulation Cardiovascular Interventions (2025)
Closed Access
Jesper Kjærgaard, Christian H. Møller, Sebastian Wiberg, et al.
Circulation Cardiovascular Interventions (2025)
Closed Access
Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study
David M. Williams, Aliya Mohd Ruslan, Rahim Ullah, et al.
Diabetes Therapy (2021) Vol. 12, Iss. 3, pp. 801-811
Open Access | Times Cited: 26
David M. Williams, Aliya Mohd Ruslan, Rahim Ullah, et al.
Diabetes Therapy (2021) Vol. 12, Iss. 3, pp. 801-811
Open Access | Times Cited: 26
Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist
Courtney J. Riedinger, Julia Sakach, Jill M. Maples, et al.
Gynecologic Oncology (2024) Vol. 190, pp. 1-10
Closed Access | Times Cited: 2
Courtney J. Riedinger, Julia Sakach, Jill M. Maples, et al.
Gynecologic Oncology (2024) Vol. 190, pp. 1-10
Closed Access | Times Cited: 2
Non-albuminuric Diabetic Kidney Disease Phenotype: Beyond Albuminuria
Luis D’Marco, Xavier Guerra, Iris Viejo-Boyano, et al.
touchREVIEWS in Endocrinology (2022) Vol. 18, Iss. 2, pp. 102-102
Open Access | Times Cited: 11
Luis D’Marco, Xavier Guerra, Iris Viejo-Boyano, et al.
touchREVIEWS in Endocrinology (2022) Vol. 18, Iss. 2, pp. 102-102
Open Access | Times Cited: 11
Recent developments in GLP‐1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class
Evie Bain, Stephen C. Bain
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. S3, pp. 30-39
Open Access | Times Cited: 14
Evie Bain, Stephen C. Bain
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. S3, pp. 30-39
Open Access | Times Cited: 14
Semaglutide-Associated Acute Interstitial Nephritis: A Case Report
Megan Borkum, Wynnie Lau, Paula Blanco, et al.
Kidney Medicine (2022) Vol. 4, Iss. 12, pp. 100561-100561
Open Access | Times Cited: 9
Megan Borkum, Wynnie Lau, Paula Blanco, et al.
Kidney Medicine (2022) Vol. 4, Iss. 12, pp. 100561-100561
Open Access | Times Cited: 9
Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
Panagiotis I. Georgianos, Vasilios Vaios, Stefanos Roumeliotis, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 2, pp. 223-223
Open Access | Times Cited: 8
Panagiotis I. Georgianos, Vasilios Vaios, Stefanos Roumeliotis, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 2, pp. 223-223
Open Access | Times Cited: 8
SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
Luis D’Marco, Valery Morillo, José Luis Górriz, et al.
Journal of Diabetes Research (2021) Vol. 2021, pp. 1-17
Open Access | Times Cited: 8
Luis D’Marco, Valery Morillo, José Luis Górriz, et al.
Journal of Diabetes Research (2021) Vol. 2021, pp. 1-17
Open Access | Times Cited: 8
The Regulation of Metabolic Homeostasis by Incretins and the Metabolic Hormones Produced by Pancreatic Islets
Joshua L. Reed, Stephen C. Bain, Venkateswarlu Kanamarlapudi
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 2419-2456
Open Access
Joshua L. Reed, Stephen C. Bain, Venkateswarlu Kanamarlapudi
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 2419-2456
Open Access
Diabetic Nephropathy
Jenny Kelly, Richard Solomon
Contemporary cardiology (2023), pp. 527-550
Closed Access | Times Cited: 1
Jenny Kelly, Richard Solomon
Contemporary cardiology (2023), pp. 527-550
Closed Access | Times Cited: 1
How to Use Type 2 Diabetes Treatments in Clinical Practice
Thomas Karagiannis, Aris Liakos, Απόστολος Τσάπας
(2024), pp. 534-550
Closed Access
Thomas Karagiannis, Aris Liakos, Απόστολος Τσάπας
(2024), pp. 534-550
Closed Access
Diabetes mellitus: what the neurologists need to know
Jeffrey W. Stephens, David M. Williams, Richard Chudleigh
Practical Neurology (2022) Vol. 22, Iss. 6, pp. 532-539
Closed Access | Times Cited: 2
Jeffrey W. Stephens, David M. Williams, Richard Chudleigh
Practical Neurology (2022) Vol. 22, Iss. 6, pp. 532-539
Closed Access | Times Cited: 2
The economic side of an oral sugar lowering therapy intensification by glucagon-like peptidt-1 receptor agonists
S. К. Zyryanov, I. N. Dyakov
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice (2022), Iss. 4, pp. 4-15
Open Access
S. К. Zyryanov, I. N. Dyakov
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice (2022), Iss. 4, pp. 4-15
Open Access
